A better understanding of the molecular drivers of tumor progression and recurrence, such as the roles of NF2, SMO, AKT1, TRAF7, and KLF4 mutations, will facilitate the development of targeted therapies, potentially improving outcomes for patients with atypical and anaplastic meningiomas [45]. This evidence concerns the gene TRAF7 and meningioma.